Skip to main content

Table 3 Monthly effectiveness of T14 and ISD treatments to eliminate Plasmodium vivax recurrent infections in patients of southern Mexico

From: Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico

A. T14; N = 37

 Day of sampling (mean/SD)

29/3

59/8

92/5

124/4

152/6

185/5

214/5

247/4

277/6

305/7

336/6

370/11

 n, samples

35

33

34

30

28

28

28

25

23

25

23

27

 n 1rst P. vivax recurrence

0

0

0

0

0

0

2

1

0

1

0

0

 Cumulative lost

0

0

0

0

0

1

3

4

4

4

5

6

 % Effectiveness

100

100

100

100

100

100

94.1

90.9

90.9

87.8

87.5

87.1

B. ISD; N = 49

 Day of sampling (mean/SD)

29/3a

62/4a

93/6

121/8

154/6

187/7a

218/7a

246/7a

278/11

306/12

336/10

367/22

 n, samples

49

48

46

42

40

39

34

28

24

24

22

20

 n, 1rst P. vivax recurrence

2

1

2

1

0

1

1

3

3

2

1

1

 Cumulative lost

0

0

0

2

2

6

9

12

12

12

12

13

 % Effectiveness

95.9

93.8

89.7

87.2

87.2

83.7

80

70.2

62.1

56.7

54

50

 P valueb

0.214

0.126

0.045

0.023

0.023

0.011

0.076

0.031

0.005

0.003

0.002

0.001

  1. Only patients that completed at least 3 months of follow up were included in this table; four patients under T14 and 18 under ISD had at least one recurrent blood infection; a recurrent blood infection was diagnosed by RDT and/or microscopy or PCR (only two patients; P45 and P63)
  2. Percentage effectiveness was calculated as the number of patients with no malaria infection divided by the total of patients under follow-up
  3. N number of patients, SD standard deviation
  4. aISD was provided
  5. bZ-test, comparing T14 and ISD, showing the proportions of patients with recurrent infections, at 95 % confidence